Physician profile
Narinder Singh
NPI 1841867439
$1,987.85
in general payments reported to CMS, 2019-2025
25 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.74 · 2024: $141 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.32 | 2025 | |
| Indivior INC. | $349.64 | 2025 | Sublocade |
| Alkermes, INC. | $148.97 | 2025 | Vivitrol |
| Lundbeck LLC | $138.27 | 2025 | Rexulti |
| Pfizer INC. | $123.03 | 2025 | |
| Novo Nordisk INC | $98.78 | 2025 | Wegovy, Saxenda |
| Almatica Pharma LLC | $80.54 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $73.98 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $73.28 | 2024-2025 | Rexulti |
| Viiv Healthcare Company | $64.05 | 2025 | Apretude |
| Astrazeneca Pharmaceuticals LP | $50.03 | 2025 | Breztri |
| Braeburn INC. | $39.30 | 2025 | Brixadi |
| Gilead Sciences, INC. | $39.26 | 2024-2025 | |
| Exact Sciences Corporation | $35.68 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ibsa Pharma INC. | $35.64 | 2025 | Tirosint, Licart, Flector |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.21 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $34.90 | 2025 | Capvaxive, Gardasil 9, M-M-R II |
| Ardelyx, INC. | $31.81 | 2025 | Ibsrela |
| Eisai INC. | $29.70 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.21 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $25.95 | 2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $23.27 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $20.70 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $17.59 | 2025 | Contrave |
| Organon LLC | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.